ArticleNucleic acids research2026
Three-dimensional structure of the palbociclib-HIV TAR complex.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We present the structure of the HIV-1 transactivation response (TAR) element bound to the kinase inhibitor palbociclib, a single-digit nM ligand and low nM inhibitor of assembly of the super elongation complex. The small molecule rearranges the RNA to create a deep binding pocket within a new structure of TAR. It displaces A22 to form an "intermolecular pair" with U40, generating a continuously stacked 11 base-pair helix, which includes three new base triples involving A22 itself and the UCU bulge nucleotides. Mutation of nucleotides within the binding pocket or small modifications of the small molecule that abrogate high-affinity binding also disrupt direct intermolecular contacts or interactions that stabilize the RNA structure required for binding. It is highly unlikely that such an extensive combination of sequence and structural requirements is duplicated anywhere else in the transcriptome and in a functional context. This structure demonstrates that RNA refolding in response to small molecule binding is key both to providing potent and specific interactions and to eliciting a biochemical response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.